Oslo, 5 May 2022 - Navamedic ASA ("NAVA" or the "Company") (OSE: NAVA) today
announces that it has entered into a share purchase agreement with Agnvicen AB
to acquire 100% of the shares in Impolin AB for a purchase price of SEK 50
million on a debt and cash free basis. In addition, the seller may be entitled
to an additional consideration in the amount of SEK 5 million if certain
pre-agreed milestones for Impolin AB are satisfied by year-end 2022.

Navamedic will settle SEK 25 million of the purchase price by way of issuing new
shares to the seller through conversion of an account receivable to be issued by
Navamedic to the seller at closing. The remaining portion of the purchase price
will be settled in cash. The subscription price for the new shares shall be
equal to the volume weighted average share price of the Company's shares on the
Oslo Stock Exchange during the period from 31 December 2021 to the closing date
of the transaction. The consideration shares will be listed on the Oslo Stock
Exchange and be subject to a lock-up period of 24 months from the closing date.
The board of directors of Navamedic will issue the consideration shares pursuant
to an authorization to issue new shares granted to it by the general meeting of
the Company on 3 June 2021 or, if completion occurs after the expiry of such
authorization, a new authorization to be approved by the Annual General Meeting
of the Company.

The completion of the transaction is subject to Impolin AB amending one of its
material agreements on terms and conditions satisfactory to Navamedic, in
addition to certain customary conditions. It is expected that the transaction
will be completed during Q2 2022.

Upon closing of the transaction, Impolin AB will become a 100% wholly owned
subsidiary of Navamedic ASA. Impolin AB is a Stockholm based company that
specializes in products related to the pre- and post-treatment for bariatric
surgery and has built a strong position in Sweden for the products Modifast and
MedMade.

---

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation article 7 and is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock
exchange announcement was published by Lars Hjarrand, CFO of Navamedic, on 5 May
2022 at 10:20 CEST on behalf of the Company.

--

For further information, please contact: 
Kathrine Gamborg Andreassen, CEO, Navamedic 
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com 

Lars Hjarrand, CFO, Navamedic 
Mobile: +47 917 62 842 
E-mail: lars.hjarrand@navamedic.com 

About Navamedic 
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com